LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2020/015915, filed Jan 30, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,214,614 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF In force · Medium confidence | Scholar Rock, Inc. | In force | Medium confidence | ||
| US 11,365,245 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF In force · Low confidence | Scholar Rock, Inc. | In force | Low confidence | ||
| US 12,173,059 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF In force · Medium confidence | Scholar Rock, Inc. | In force | Medium confidence | ||
| Application 18/941,156 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF Pending Not granted | Scholar Rock, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Scholar Rock, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.